New booster aims to shield the vulnerable from COVID-19

NCT ID NCT05303402

Completed ⭐️ VACCINE ⭐️ Sponsor: Hipra Scientific, S.L.U Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested an extra dose of the HIPRA COVID-19 vaccine in 241 adults with conditions like HIV, kidney disease, or autoimmune disorders that weaken the immune system. The goal was to see if the booster raises antibody levels against virus variants and remains safe. Researchers measured immune responses before and 14 days after the shot, with follow-ups up to a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HIPRA COVID-19 vaccine (PHH-1V)
What this could lead to: If successful, this could provide a safe and effective booster option for people with weakened immune systems, helping them stay protected against COVID-19 variants.
What could go wrong: This is a mid-stage trial with only 241 participants and no comparison group, so results may not apply to everyone. The vaccine may not work as well in all immunosuppressed individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease common variable immunodeficiency end stage renal failure HIV infectious disease COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS-COV-2 INFECTION

Contacts and locations

Locations

Ankara University Medical Faculty Hospitals

Ankara, Ankara, 06620, Turkey (Türkiye)
Hacettepe University Medical Faculty Hospitals

Ankara, Ankara, 06230, Turkey (Türkiye)
Hospital Clínic de Barcelona

Barcelona, Barcelona, 08036, Spain
Hospital Germans Trias i Pujol

Badalona, Barcelona, 08916, Spain
Hospital Josep Trueta

Girona, Girona, 17001, Spain
Koc University Hospital

Istanbul, Istanbul, 34010, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.